Prior to initiation of effective antiviral therapy, components of the HIV viral machinery (such as transactivating protein, or Tat) promote KSHV survival and tumorigenesis within infected cells, leading to continued infection and potential malignant transformation [8,9]. The gene discussed is TAT; the disease is infection.